Clinical characteristics correlation between solute carrier family 7 member 11 gene SLC7A11 and liver cancer.

Objective To determine the expression level of SLC7A11 gene (solute carrier family 7 member 11) in liver cancer and its adjacent tissues, and to understand the relationship between SLC7A11 gene and the clinical characteristics of liver cancer patients. Methods The expression level of SLC7A11 gene in 102 liver cancer tissues and their adjacent tissues was determined by semi-quantitative PCR and real-time PCR, and the relationship between SLC7A11 gene and age, sex, tumor size, HBV infection, lymph node metastasis, survival time and histological grade of liver cancer patients was analyzed. Results Semi-quantitative PCR of SLC7A11 gene in 85.0% (17/20) liver cancer tissues was significantly up-regulated compared with that in paracancerous tissues. Real-time PCR was used to detect SLC7A11 mRNA expression in 102 liver cancer and paracancerous tissues, and SLC7A11 mRNA expression was significantly up-regulated in 72.5% (74/102) liver cancer tissues (P<0.01). The average survival time of the SLC7A11 mRNA high expression group (64 cases) was 16 months, the average survival time of the low expression group was 22 months, and the survival time of the SLC7A11 mRNA high expression group was shorter (P<0.01). SLC7A11 mRNA expression was significantly up-regulated in liver cancer patients with tumors larger than 3 cm, SLC7A11 gene expression level was positively correlated with tumor size (P<0.05), but not with age, sex, HBV infection, lymph node metastasis or histological grade (all P>0.05). Conclusion SLC7A11 expression is up-regulated in hepatocellular carcinoma, which affects tumor proliferation and survival of patients, suggesting that SLC7A11 plays an important role in the occurrence and development of hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]